Baird raised the firm’s price target on Labcorp (LH) to $311 from $302 and keeps an Outperform rating on the shares. The company reported strong Q2 results and is seeing favorable volume and mix trends, the analyst tells investors in a research note. However, with the stock near all-time highs, Baird would prefer to buy Labcorp at lower levels.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp launches first FDA-cleared blood test for Alzheimer’s disease
- Labcorp achieves IVDR CE-Marking for PGDx elio tissue complete in the EU
- Labcorp price target raised to $305 from $282 at UBS
- Labcorp price target raised to $310 from $290 at Truist
- Labcorp price target raised to $302 from $290 at Baird